VRCA: Phase III programs for common warts and BCC advance rapidly, with strong efficacy and global expansion
Significant progress was highlighted in commercializing YCANTH for molluscum and advancing global phase III trials for common warts, with strong efficacy and safety data. VP-315 for basal cell carcinoma is phase III-ready, showing high response rates and expedited regulatory pathways.Based on Verri…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.